RESPIRATORY REHABILITATION, A PUBLIC HEALTH CHALLENGE
COPD affects nearly 392 million people worldwide¹ and around 3.5 million in France². It accounts for 100,000 to 150,000 hospitalisations for exacerbation every year³. LORIO was designed to address this challenge, alongside healthcare professionals.
ORGANISATIONAL CHALLENGE
< 10 %
of COPD patients take part in a pulmonary rehabilitation programme⁴
———
LORIO supports physiotherapists and rehabilitation centres: personalised sessions and progress tracking for each patient, in private practice or in a centre.
HUMAN CHALLENGE
100 %
of exercises guided by real-time biofeedback
———
Alone at home, patients doubt they are doing their exercises correctly, and that doubt is discouraging. Biofeedback shows them whether their breathing matches the recommended exercise: every session becomes a playful challenge.
HEALTH CHALLENGE
1 in 5
patients rehospitalised for exacerbation within six months⁵
———
Maintaining the gains of rehabilitation is a key lever. The risk of dropping out is highest once patients return home: HAPPLYZ Medical is evaluating LORIO DTx over 12 months post-rehabilitation.
ECONOMIC CHALLENGE
€3.5bn
estimated annual cost of COPD to society⁶
———
Hospitalisations for exacerbation amounted to €678M in 2012, up 12.6% in five years⁷. A rehospitalised patient costs twice as much: €16,275 versus €8,208⁵.
SOURCES
¹ Adeloye D. et al., Lancet Respir Med, 2022 · ² HAS; Santé respiratoire France · ³ Santé publique France, 2015 data · ⁴ HAS, 2014; La Revue du Praticien, 2020 · ⁵ Cavailles A. et al., Int J COPD, 2020 · ⁶ French COPD Plan 2005-2010, Ministry of Health, cited by HAS · ⁷ Molinari N. et al., Respiratory Research, 2016
OUR STORY...
Our story began while preparing for a hackathon, RespirH@cktion, held at Lille University Hospital in late November 2019. It was there that we met patients with chronic respiratory diseases (severe asthma and COPD), some of them on oxygen therapy. The jury, made up of patients, patient associations, pulmonologists and healthcare facility managers, awarded us the Jury’s Coup de Cœur Prize.
Making respiratory rehabilitation accessible, attractive and motivating for all these patients is a public health challenge.
CEO, co-founder
Vanessa LESOBRE
CTO, co-founder
Maxime BERRIOT
OVER THE WIND...
-
Marketing
May 2023
The LORIO device is now on sale.
-
Production
January 2023
After promising pre-sales, we were able to launch production of LORIO on a human scale. Thanks to you who made this possible!
-
Pre-sales
October 2022
This is the long-awaited launch of pre-sales for our LORIO solution !
-
CE Medical Certification
August 2022
LORIO becomes a CE Class 1 Medical Device.
-
Industrialization
June 2022
Our product changes its name to “LORIO”. A nod to its namesake, the oriole bird, known for its fluty and remarkably clear song.
-
HAPPLYZ Medical
April 2021
Accompanied and guided by Eurasanté and our mentors, we founded the company HAPPLYZ Medical in order to launch the production of our project.
-
Eurasanté Incubation
October 2020
We are joining the Eurasanté incubator, thanks to which we were able to develop and present our project to a health network.
-
Patent Filing
June 2020
Following the POC, we were able to protect and certify our product with the filing of the patent.
-
POC design
May 2020
The Proof of Concept (POC) is essential. This feasibility study allowed us to demonstrate the viability of our idea.
-
RespirH@cktion
November 2019
The project was born during the RespirH@cktion hackathon, it was designed and developed during 1 month of intensive challenge. Presented before a jury, our idea, initially called "Un Air de Flûte", won the Jury's Favorite Prize.

